Q1 2026 ALX Oncology Holdings Inc Earnings Call Transcript
Greetings, and welcome to the ALX Oncology first quarter 2026 financial results conference and webcast. At this time, all participants are in a listen-only mode. (Operator Instructions) Please note, this conference is being recorded.
I will now turn the conference over to your host, Jason Letrmann, CEO. Please go ahead, sir.
Thanks, everyone, and welcome to our Q1 2026 results. I really appreciate you all spending time with us this morning and are looking forward to sharing these updates with you. On slide 2, and before we start our presentation of housekeeping, here are our forward-looking statements for your review. On slide 3, here's the agenda and plan for today.
We're going to be providing an update on our key accomplishments in the first quarter of 2026. Most notably, we are very excited to share with you the dataset that was presented yesterday in Munich at ESMO Breast 2026 from the analysis of our trial evaluating evorpercept and zanidatimab, which clearly
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
